Bioporto A/S
CSE:BIOPOR
Bioporto A/S
Cash from Operating Activities
Bioporto A/S
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash from Operating Activities
-kr68.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-17%
|
|
|
Genmab A/S
CSE:GMAB
|
Cash from Operating Activities
kr7.8B
|
CAGR 3-Years
52%
|
CAGR 5-Years
42%
|
CAGR 10-Years
50%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash from Operating Activities
-kr930.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-36%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash from Operating Activities
-€306.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-32%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash from Operating Activities
kr1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Cash from Operating Activities
-kr72.2m
|
CAGR 3-Years
39%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Cash from Operating Activities?
Cash from Operating Activities
-68.7m
DKK
Based on the financial report for Sep 30, 2024, Bioporto A/S's Cash from Operating Activities amounts to -68.7m DKK.
What is Bioporto A/S's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-17%
Over the last year, the Cash from Operating Activities growth was 1%. The average annual Cash from Operating Activities growth rates for Bioporto A/S have been -6% over the past three years , -6% over the past five years , and -17% over the past ten years .
You don't have any saved screeners yet